格隆汇8月6日丨康希诺生物(06185.HK)宣布，董事会会议将于2025年8月20日（星期三）举行，藉以 （其中包括）考虑及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布，以及考 虑建议派发中期股息（如有）。 ...

（股份代號：6185） 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2025年8月20日（星 期 三）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2025年6月30日止六個月的中期業績及其發佈，以及考慮建議派發中 期 股 息（如 有）。 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 香港，2025年8月6日 於本通告日期，本公司董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博 士 及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠 先生及張耀樑先生。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | | 0 | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Viewpoint - The recent surge in the stock prices of CanSino Biologics (6185.HK) is attributed to a warning from the World Health Organization regarding mosquito-borne diseases, particularly Chikungunya fever, which has heightened market sentiment towards the vaccine sector [1]. Group 1: Stock Performance - CanSino Biologics experienced a significant stock increase, rising over 16.8% to a peak of 55.7 HKD, marking a new high since March 2023 [1]. - The A-share market also saw a rise of over 11%, reaching a maximum of 92.7 CNY, the highest since August 2023 [1]. Group 2: Disease Outbreak - The Guangdong Provincial Center for Disease Control reported 2,892 new local cases of Chikungunya fever from July 27 to August 2 [1]. Group 3: Product Development - CanSino has made important advancements in the research and commercialization of multiple products in the second half of this year [1]. - The company announced that its trivalent inactivated poliovirus vaccine (Sf-RVN cells) has received approval from the National Medical Products Administration of China to commence clinical trials [1]. - On June 20, CanSino disclosed that its 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin) has been approved for new drug listing by the National Medical Products Administration [1].

Group 1 - The stock price of CanSino Biologics (06185.HK) increased by over 10% for H-shares, while A-shares rose by 7.6% [1]

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

Group 1 - The core viewpoint highlights the strong performance and growth of the Kexin Pharmaceutical ETF managed by Jiashi, with significant trading activity and inflows [2] - As of August 4, the Kexin Pharmaceutical ETF Jiashi has seen a weekly average trading volume of 58.54 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 12.30 million yuan over the past two weeks, also leading among comparable funds [2] - The fund's net asset value has risen by 50.01% over the past year, placing it in the top 15.64% of index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - The biopharmaceutical industry is expected to stabilize and grow throughout 2025, supported by favorable policies for innovative drug development and medical equipment updates [5] - The transition to the 2.0 era of innovative drugs in China is marked by a qualitative improvement, with domestic new drugs expected to participate deeply in the global market over the next decade [4]

Group 1 - The Hong Kong biotechnology sector experienced a rise on August 5, with notable increases in stock prices for several companies [1] - Gilead Sciences (歌礼制药) saw a surge of over 15% in its stock price [1] - Ascentage Pharma (亚盛医药) increased by more than 9% [1] - Other companies such as Jiahe Biopharma (嘉和生物) and Innovent Biologics (复宏汉霖) rose by over 8% [1] - CanSino Biologics (康希诺生物) and Zai Lab (再鼎医药) experienced increases of over 5% [1]

前十大AH股偏离值排行 | 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 安德利果汁(02218) | 19.660 | 51.81 | 215.67% | 37.63% | | 金力永磁(06680) | 18.400 | 27.36 | 78.10% | 22.60% | | 农业银行(01288) | 5.150 | 6.3 | 46.60% | 13.83% | | 康希诺生物(06185) | 44.800 | 80.46 | 115.11% | 11.56% | | 昭衍新药(06127) | 23.950 | 32.34 | 61.75% | 11.02% | | 北京北辰实业股份 (00588) | 0.870 | 1.78 | 144.83% | 10.74% | | 复旦张江(01349) | 4.090 | 10.86 | 218.09% | 10.71% | | 山东墨龙(00568) | 4.410 | 6.36 | 72.79% | 9.57% | | --- | --- | --- | -- ...

疫苗股继续活跃，其中，康希诺AH股午后拉升，A股一度涨超16%报82.48元，股价创2023年12月以来新高；H股拉升一度涨近14%报48.55港元，股价创 2023年3月以来新高。 随着确诊病例数量的增加，以及世界卫生组织专家发出的警报，市场对相关疫苗的需求预期显著增强，刺激疫苗股获资金追捧。 消息面上，基孔肯雅热在广东佛山市的爆发继续成为市场关注的焦点。据广东省疾控局消息，2025年7月20日0时至7月26日24时，广东省新增报告2940例 基孔肯雅热本地病例，未报告重症和死亡病例。病例分布在佛山2882例，广州22例，中山18例，东莞、珠海、河源各3例，江门、阳江、肇庆各2例，清 远、深圳、湛江各1例。 ...